{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T15:21:17Z","timestamp":1778858477853,"version":"3.51.4"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,7]],"date-time":"2021-09-07T00:00:00Z","timestamp":1630972800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,9,7]],"date-time":"2021-09-07T00:00:00Z","timestamp":1630972800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100014103","name":"key technology research and development program of shandong","doi-asserted-by":"publisher","award":["2020YFC2008305"],"award-info":[{"award-number":["2020YFC2008305"]}],"id":[{"id":"10.13039\/100014103","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012401","name":"beijing science and technology planning project","doi-asserted-by":"publisher","award":["D181100000218002"],"award-info":[{"award-number":["D181100000218002"]}],"id":[{"id":"10.13039\/501100012401","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1007\/s11096-021-01316-0","type":"journal-article","created":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T15:57:51Z","timestamp":1634140671000},"page":"90-99","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Physician-pharmacist collaborative management in patients after percutaneous coronary intervention: a retrospective propensity score matching cohort study"],"prefix":"10.1007","volume":"44","author":[{"given":"Qingxia","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haofan","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangrong","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suying","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoling","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,9,7]]},"reference":[{"issue":"10","key":"1316_CR1","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1161\/CIR.0000000000000659","volume":"139","author":"EJ Benjamin","year":"2019","unstructured":"Benjamin EJ, Muntner P, Alonso A, et al. Heart disease and stroke statistics-2019 update: a report from the american heart association. Circulation. 2019;139(10):e56\u2013528.","journal-title":"Circulation"},{"key":"1316_CR2","unstructured":"The Writing Committee of the Report on Cardiovascular Health and Desease in China. Report on Cardiovascular Health and Disases in China 2019: an Updated Summary. Chinese Circulation Journal. 2020;35(9): 833\u2013854."},{"issue":"10204","key":"1316_CR3","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1016\/S0140-6736(19)30427-1","volume":"394","author":"M Zhou","year":"2019","unstructured":"Zhou M, Wang H, Zeng X, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990\u20132017: a systematic analysis for the global burden of disease study 2017. Lancet (London, England). 2019;394(10204):1145\u201358.","journal-title":"Lancet (London, England)"},{"key":"1316_CR4","unstructured":"Xu YM. Study on the status and prognosis of secondary prevention in patients with coronary heart disease after PCI. Chinese Circulation Journal. 2015(z1):59\u201359."},{"issue":"10022","key":"1316_CR5","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S0140-6736(15)01225-8","volume":"387","author":"D Ettehad","year":"2016","unstructured":"Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. The Lancet. 2016;387(10022):957\u201367.","journal-title":"The Lancet"},{"issue":"24","key":"1316_CR6","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1161\/CIRCULATIONAHA.116.022194","volume":"133","author":"CC Low Wang","year":"2016","unstructured":"Low Wang CC, Hess CN, Hiatt WR, et al. Clinical update: cardiovascular disease in diabetes mellitus: atherosclerotic cardiovascular disease and heart failure in type 2 diabetes mellitus - mechanisms, management, and clinical considerations. Circulation. 2016;133(24):2459\u2013502.","journal-title":"Circulation"},{"key":"1316_CR7","doi-asserted-by":"crossref","unstructured":"Cholesterol Treatment Trialists' Collaboration, Fulcher J, O'Connell R, et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174\u2008000 participants in 27 randomised trials. The Lancet. 2015;385(9976):1397\u20131405.","DOI":"10.1016\/S0140-6736(14)61368-4"},{"issue":"19","key":"1316_CR8","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1001\/jama.288.19.2411","volume":"288","author":"SR Steinhubl","year":"2002","unstructured":"Steinhubl SR, Berger PB, Mann JT, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288(19):2411\u201320.","journal-title":"JAMA"},{"issue":"7200","key":"1316_CR9","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1136\/bmj.318.7200.1730","volume":"318","author":"N Freemantle","year":"1999","unstructured":"Freemantle N, Cleland J, Young P, et al. beta Blockade after myocardial infarction: systematic review and meta regression analysis. BMJ (Clinical research ed). 1999;318(7200):1730\u20137.","journal-title":"BMJ (Clinical research ed)"},{"issue":"11","key":"1316_CR10","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1093\/eurheartj\/ehp103","volume":"30","author":"JJ Brugts","year":"2009","unstructured":"Brugts JJ, Ninomiya T, Boersma E, et al. The consistency of the treatment effect of an ACE-inhibitor based treatment regimen in patients with vascular disease or high risk of vascular disease: a combined analysis of individual data of ADVANCE, EUROPA, and PROGRESS trials. Eur Heart J. 2009;30(11):1385\u201394.","journal-title":"Eur Heart J"},{"issue":"20","key":"1316_CR11","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1056\/NEJMoa032292","volume":"349","author":"MA Pfeffer","year":"2003","unstructured":"Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349(20):1893\u2013906.","journal-title":"N Engl J Med"},{"key":"1316_CR12","unstructured":"Yang X, Li P. Analysis of the Current Situation and Influence Factors of Secondary Prevention after PCI in Patients with Coronary Heart Disease. J Guiyang Med College. 2015;40(12):1417\u20131419,1423"},{"issue":"3","key":"1316_CR13","first-page":"450","volume":"51","author":"ZH Ji","year":"2016","unstructured":"Ji ZH, Xu Y. On the current status of secondary prevention and its impact factors on patients after PCI treatment. Acta Universitatis Medicinalis Anhui. 2016;51(3):450\u20133.","journal-title":"Acta Universitatis Medicinalis Anhui"},{"issue":"4","key":"1316_CR14","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1111\/j.1751-7176.2008.07434.x","volume":"10","author":"BL Carter","year":"2008","unstructured":"Carter BL, Bergus GR, Dawson JD, et al. A cluster randomized trial to evaluate physician\/pharmacist collaboration to improve blood pressure control. J Clin Hypertens (Greenwich). 2008;10(4):260\u201371.","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"21","key":"1316_CR15","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1001\/archinternmed.2009.358","volume":"169","author":"BL Carter","year":"2009","unstructured":"Carter BL, Ardery G, Dawson JD, et al. Physician and pharmacist collaboration to improve blood pressure control. Arch Intern Med. 2009;169(21):1996\u20132002.","journal-title":"Arch Intern Med"},{"issue":"3","key":"1316_CR16","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1161\/CIRCOUTCOMES.114.001283","volume":"8","author":"BL Carter","year":"2015","unstructured":"Carter BL, Coffey CS, Ardery G, et al. Cluster-randomized trial of a physician\/pharmacist collaborative model to improve blood pressure control. Circ Cardiovasc Qual Outcomes. 2015;8(3):235\u201343.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"1","key":"1316_CR17","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/jep.12606","volume":"24","author":"PM Aguiar","year":"2018","unstructured":"Aguiar PM, da Silva CHP, Chiann C, et al. Pharmacist-physician collaborative care model for patients with uncontrolled type 2 diabetes in Brazil: results from a randomized controlled trial. J Eval Clin Pract. 2018;24(1):22\u201330.","journal-title":"J Eval Clin Pract"},{"issue":"14","key":"1316_CR18","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.2146\/ajhp170789","volume":"75","author":"GR Matzke","year":"2018","unstructured":"Matzke GR, Moczygemba LR, Williams KJ, et al. Impact of a pharmacist-physician collaborative care model on patient outcomes and health services utilization. Am J Health-Syst Pharmacy\u202f: AJHP\u202f: Offic J Am Soc Health-Syst Pharmacists. 2018;75(14):1039\u201347.","journal-title":"Am J Health-Syst Pharmacy : AJHP : Offic J Am Soc Health-Syst Pharmacists"},{"key":"1316_CR19","unstructured":"www.scio.gov.cn. Notice on Issuing the Action Plan for Further Improvement of Medical Services (2018\u20132020) [Eb\/Ol]. http:\/\/www.scio.gov.cn\/32344\/32345\/37799\/38232\/xgzc38238\/Document\/1627572\/1627572.htm. Accessed 2018\u201301\u201304."},{"key":"1316_CR20","doi-asserted-by":"publisher","first-page":"783","DOI":"10.2147\/PPA.S156734","volume":"12","author":"X Li","year":"2018","unstructured":"Li X, Sun S, Wang Q, et al. Assessment of patients\u2019 warfarin knowledge and anticoagulation control at a joint physician- and pharmacist-managed clinic in China. Patient Prefer Adherence. 2018;12:783\u201391.","journal-title":"Patient Prefer Adherence"},{"key":"1316_CR21","doi-asserted-by":"crossref","unstructured":"Liu K, Huang H, Zhang L, et al. Effects of a physician- and pharmacist-managed clinic on pain management in cancer patients in China. Basic & clinical pharmacology & toxicology. 2021.","DOI":"10.1111\/bcpt.13583"},{"key":"1316_CR22","unstructured":"Joint committee issued Chinese guideline for the management of dyslipidemia. 2016 Chinese guideline for the management of dyslipidemia in adults. Chinese Circulation Journal. 2016;31(10):937\u2013950."},{"key":"1316_CR23","unstructured":"Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology. 2014;63(25 Pt B):2889\u20132934."},{"key":"1316_CR24","doi-asserted-by":"crossref","unstructured":"Rabar S, Harker M, O'Flynn N, et al. Lipid modification and cardiovascular risk assessment for the primary and secondary prevention of cardiovascular disease: summary of updated NICE guidance. BMJ (Clinical research ed). 2014;349:g4356.","DOI":"10.1136\/bmj.g4356"},{"key":"1316_CR25","unstructured":"Committee of Experts on Rational Drug Use National Health and Family Planning Commission of the P.R. China, Chinese Pharmacists Association. Guidelines for the rational use of drugs for coronary heart disease (2nd edition). Chinese Journal of the Frontiers of Medical Science (Electronic Version). 2018(6):1\u2013130."},{"key":"1316_CR26","unstructured":"Pharmaceutical care network Europe foudation. PCNE classification for drug related problems V9.0[EB\/OL]. (2019\u201306\u201330)[2020\u201310\u201301]. http:\/\/www.pcne.org\/upload\/files\/410_PCNE_classification_V9-0m.pdf."},{"issue":"11","key":"1316_CR27","first-page":"1597","volume":"35","author":"FQ Huang","year":"2015","unstructured":"Huang FQ, Du CL, Sun MH, et al. Propensity score matching in SPSS. J South Med Univ. 2015;35(11):1597\u2013601.","journal-title":"J South Med Univ"},{"issue":"7","key":"1316_CR28","first-page":"823","volume":"31","author":"YJ Wang","year":"2010","unstructured":"Wang YJ, Cai HW, Xia JL, et al. Propensity score (III) Key issues in practice of propensity score. Chin J Epidemiol. 2010;31(7):823\u20135.","journal-title":"Chin J Epidemiol"},{"key":"1316_CR29","doi-asserted-by":"crossref","unstructured":"Banach M, Penson PE, Vrablik M, et al. Optimal use of lipid-lowering therapy after acute coronary syndromes: A Position Paper endorsed by the International Lipid Expert Panel (ILEP). Pharmacological research. 2021;166:105499.","DOI":"10.1016\/j.phrs.2021.105499"},{"issue":"11","key":"1316_CR30","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1345\/aph.1G356","volume":"39","author":"PJ Kiel","year":"2005","unstructured":"Kiel PJ, McCord AD. Pharmacist impact on clinical outcomes in a diabetes disease management program via collaborative practice. Ann Pharmacother. 2005;39(11):1828\u201332.","journal-title":"Ann Pharmacother"},{"issue":"11","key":"1316_CR31","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1177\/1060028013504738","volume":"47","author":"A Howard-Thompson","year":"2013","unstructured":"Howard-Thompson A, Farland MZ, Byrd DC, et al. Pharmacist-physician collaboration for diabetes care: cardiovascular outcomes. Ann Pharmacother. 2013;47(11):1471\u20137.","journal-title":"Ann Pharmacother"},{"issue":"4","key":"1316_CR32","doi-asserted-by":"publisher","first-page":"295","DOI":"10.18553\/jmcp.2011.17.4.295","volume":"17","author":"EA Hammad","year":"2011","unstructured":"Hammad EA, Yasein N, Tahaineh L, et al. A randomized controlled trial to assess pharmacist-physician collaborative practice in the management of metabolic syndrome in a university medical clinic in Jordan. J Managed Care Pharmacy\u202f: JMCP. 2011;17(4):295\u2013303.","journal-title":"J Managed Care Pharmacy : JMCP"},{"issue":"5","key":"1316_CR33","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1097\/HJH.0000000000000865","volume":"34","author":"P Palatini","year":"2016","unstructured":"Palatini P, Rosei EA, Casiglia E, et al. Management of the hypertensive patient with elevated heart rate: statement of the second consensus conference endorsed by the european society of hypertension. J Hypertens. 2016;34(5):813\u201321.","journal-title":"J Hypertens"},{"issue":"2","key":"1316_CR34","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1093\/ajh\/hpv095","volume":"29","author":"AI Aladin","year":"2016","unstructured":"Aladin AI, Al Rifai M, Rasool SH, et al. The association of resting heart rate and incident hypertension: the henry ford hospital exercise testing (FIT) project. Am J Hypertens. 2016;29(2):251\u20137.","journal-title":"Am J Hypertens"},{"issue":"9798","key":"1316_CR35","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1016\/S0140-6736(11)61215-4","volume":"378","author":"S Yusuf","year":"2011","unstructured":"Yusuf S, Islam S, Chow CK, et al. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet (London, England). 2011;378(9798):1231\u201343.","journal-title":"Lancet (London, England)"},{"key":"1316_CR36","unstructured":"Tian WW, Yu ZC, Gan ZB, et al. Risk factors of hepatic dysfunction induced by atorvastatin. Chin J New Drugs Clin Rem. 2015;10 (34)."},{"key":"1316_CR37","first-page":"818","volume":"06","author":"DH Wen","year":"2013","unstructured":"Wen DH. Adverse reactions of statins and their prevention and treatment. Herald Med. 2013;06:818\u201320.","journal-title":"Herald Med"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-021-01316-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11096-021-01316-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-021-01316-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,23]],"date-time":"2022-02-23T16:20:26Z","timestamp":1645633226000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11096-021-01316-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,7]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["1316"],"URL":"https:\/\/doi.org\/10.1007\/s11096-021-01316-0","relation":{},"ISSN":["2210-7703","2210-7711"],"issn-type":[{"value":"2210-7703","type":"print"},{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,7]]},"assertion":[{"value":"23 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no conflict of interest concerning this study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}